Sanofi, a French pharmaceutical company, halted the development and production of an experimental Clostridium difficile vaccine Friday after preliminary results of a late-stage trial revealed a low probability for success, according to Reuters.
Even though the production was stopped, the company will continue to monitor vaccinated volunteers in the C. diff trialand report any findings to the medical community.
This is the latest setback to Sanofi's vaccine program. On Wednesday the company said use of its new dengue vaccine may be limited after evidence revealed the vaccine could worsen the disease in people who have not been previously exposed to the virus.